PDCD1 and neoplasm: In summary, these data suggest that angiogenesis inhibitors enhance sensitivity to anti-PD-1 therapy through multiple mechanisms, and thereby make combination treatment exhibit a stronger killing effect on tumor cells(Jin et al. 2022).